New clinical treatment plan for acute lymphoblastic leukemia after whole genome sequencing: An update of the development of new technologies for genome editing
AB Consulting LLC, P.O. Boc 351, Lansdale, Pennsylvania 19446.
Research Article
Magna Scientia Advanced Research and Reviews, 2024, 11(01), 111–127
Article DOI: 10.30574/msarr.2024.11.1.0080
Publication history:
Received on 17 March 2024; revised on 01 May 2024; accepted on 03 May 2024
Abstract:
Acute lymphoblastic leukemia (ALL) is now being reclassified into newly identified subtypes due to genetic abnormalities, Philadelphia chromosome‐like B‐lineage ALL is one of the new high‐risk subtypes characterized by genetic alterations that activate various signaling pathways, including those involving cytokine receptors, tyrosine kinases, and epigenetic modifiers. Philadelphia chromosome‐like ALL is essentially heterogeneous; however, deletion mutations in the IKZF1 gene encoding the transcription factor IKAROS underlie many cases as a key factor inducing aggressive phenotypes and poor treatment responses. WGS (whole genome sequencing) studies of ALL patients and ethnically matched controls also identified inherited genetic variations in lymphoid neoplasm‐related genes, which are likely to increase ALL susceptibility. On the contrary, Genome editing technologies offers new opportunities for tackling diseases, and genome-editing tools such as CRISPR-Cas9 are an important means of advancing functional studies of ALL through the incorporation, elimination, and modification of somatic mutations. These findings are directly relevant to clinical hematology, and further studies on this aspect could contribute to accurate diagnosis, effective monitoring of residual disease, and patient‐oriented therapies.
Keywords:
Acute lymphoblastic leukemia; Genome editing; Drug targets; Chimeric antigen receptors
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0